Soleno Therapeutics Says Death Of Patient Not Related To VYKAT XR Treatment
Sept 10 (Reuters) - Soleno Therapeutics Inc SLNO.O:
SOLENO THERAPEUTICS INC - AWARE OF SERIOUS ADVERSE EVENT IN FDA'S FAERS REGARDING PATIENT WHO DIED - SEC FILING
SOLENO THERAPEUTICS INC - CASE REPORTED AS NOT RELATED TO VYKAT XR TREATMENT - SEC FILING
SOLENO THERAPEUTICS INC - PATIENT WAS A 17-YEAR-OLD MALE WHO DIED FROM PULMONARY EMBOLUS - SEC FILING
SOLENO THERAPEUTICS INC - VYKAT XR HAS PROVEN SAFETY AND EFFICACY PROFILE - SEC FILING
Source text: [ID:n0001193125-25-199882]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey








